Clinical Trials Logo

Clinical Trial Summary

Infections due to post transplant immune deficiency are a major problem following allogeneic stem cell transplantation (Allo-SCT), particularly in patients receiving cord blood transplant (CB). Duration of neutropenia is one of the most important risk factor for invasive fungal infection (IFI). In this setting, Micafungin has been approved for antifungal prophylaxis for patients undergoing Allo-SCT. In a randomized, double-blind, comparative, phase III trial, the overall efficacy of micafungin was superior to that of fluconazole as antifungal prophylaxis during the neutropenic phase after Allo-SCT. However, very few patients in this study received a CB transplant.

This is phase IIb, prospective, open-label, non-comparative study to assess the safety of micafungin when use in prevention of IFI in neutropenic patients receiving allo-SCT using CB as source of stem cells.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01888458
Study type Interventional
Source Nantes University Hospital
Contact
Status Completed
Phase Phase 2
Start date September 2013
Completion date April 2016

See also
  Status Clinical Trial Phase
Completed NCT00412893 - Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Phase 3
Completed NCT03066011 - Registry of Patients Treated With Systemic Mold-Active Triazoles
Completed NCT04004078 - An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM
Completed NCT01576653 - Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL N/A
Enrolling by invitation NCT02510053 - Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit N/A
Completed NCT01198236 - Efficacy of Itraconazole as Secondary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation or Chemotherapy With Prior Invasive Fungal Infection Phase 4
Recruiting NCT06137690 - Factors on Therapeutic Drug Monitoring and Safety of Voriconazole in Critically Ill Elderly Patients
Completed NCT01783379 - Pharmacokinetics of Micafungin in Patients Intensive Care Unit
Completed NCT01533558 - Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates
Recruiting NCT03149562 - Association of Plasma Transfusions and Invasive Fungal Infection
Recruiting NCT04665037 - Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127) Phase 2
Terminated NCT01148160 - Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy N/A
Withdrawn NCT01185405 - Voriconazole Plasma Level in Intensive Care Unit (ICU) Patients N/A
Completed NCT00893555 - Pharmacologic Optimization of Voriconazole Phase 3
Unknown status NCT00460330 - Evaluate Three Methods for Diagnosis of Invasive Fungal Infection in Chinese Patients After HSCT N/A
Completed NCT02823132 - Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia N/A